Who
Steve E. Krognes
Director
Company insider
Files Form 4 as: Director, Guardant Health; Director, Pliant Therapeutics; CFO and Treasurer, Denali Therapeutics; Director, Gritstone bio; Director and 10% owner, Corvus Pharmaceuticals.
In numbers
- Trades disclosed
- 203
- Buys
- 0
- Sells
- 26
- Bought
- $0
- Sold
- $20.0M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 22 Mar 2016
- Last trade
- 16 Sep 2026
- Last filed
- 17 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Sep 2026filed 17 Sep 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $192K1,103 at $174.46 | filing |
| 16 Sep 2026filed 17 Sep 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $579K3,300 at $175.42 | filing |
| 16 Sep 2026filed 17 Sep 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $229K1,300 at $176.34 | filing |
| 16 Sep 2026filed 17 Sep 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $172K971 at $177.48 | filing |
| 16 Sep 2026filed 17 Sep 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $192K1,103 at $174.46 | filing |
| 16 Sep 2026filed 17 Sep 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $579K3,300 at $175.42 | filing |
| 16 Sep 2026filed 17 Sep 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $229K1,300 at $176.34 | filing |
| 16 Sep 2026filed 17 Sep 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $172K971 at $177.48 | filing |
| 30 Jun 2026filed 2 Jul 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —155 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —155 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —155 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —155 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —4,203 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —4,203 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —2,711 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —4,203 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —2,711 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —4,203 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
News
Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?GH · insidermonkey.com · 20 Oct 2026Guardant Health (NASDAQ:GH) Director Sells $19,242.08 in StockGH · themarketsdaily.com · 19 Oct 2026Guardant Health (NASDAQ:GH) Stock Price Down 6.4% – Time to Sell?GH · tickerreport.com · 8 Oct 2026
0 headlines in the last 90 days name Steve E. Krognes; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.